MedTrace Logo

A Phase II Randomized Trial of Fish Oil in Patients With Acute Lung Injury (ALI)

NCT00351533 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2011-10-03

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether fish oil (containing omega-3 fatty acids) given enterally is safe and effective in reducing lung and systemic inflammation seen in acute lung injury.

Conditions

  • Respiratory Distress Syndrome, Adult
  • Acute Lung Injury
  • Acute Respiratory Distress Syndrome

Interventions

DRUG

Fish oil (eicosapentaenoic acid and docosahexanoic acid)

Liquid fish oil 7.5cc enterally every 6 hours

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • American Thoracic Society

    collaborator OTHER

  • Acute Respiratory Distress Syndrome Foundation

    collaborator OTHER

  • American Society for Parenteral and Enteral Nutrition

    collaborator OTHER

  • University of Washington

    lead OTHER

Principal Investigators

  • Renee D. Stapleton, MD, MSc · University of Vermont

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2009-01-31
Completion
2009-08-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00351533 on ClinicalTrials.gov